Literature DB >> 24647999

Non-infectious cryoglobulinemia vasculitis (CryoVas): update on clinical and therapeutic approach.

Rodolfo Perez-Alamino1, Luis R Espinoza.   

Abstract

CryoVas is a small vessel vasculitis associated with the presence of circulating cryoglobulins. In the absence of HCV infection, several disorders have been identified in association of CryoVas. Although evidence is limited, a few studies have recently described the clinical presentation, prognosis, and therapeutic management of non-infectious CryoVas. Patients with type I CryoVas, especially associated with hematologic malignancies, have shown a worse clinical presentation. Recent studies have also identified prognostic factors in mixed CryoVas. Therapeutic management in non-infectious CryoVas remains to be defined. Overall, treatment options should be individualized based on severity of involvement. In this setting, new data have emerged regarding the role of biologic therapy in non-infectious CryoVas. Off-label use of rituximab should be highlighted, based on the assessment of benefits and risks, especially infections.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24647999     DOI: 10.1007/s11926-014-0420-0

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  23 in total

1.  Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients from a single center.

Authors:  O Trejo; M Ramos-Casals; M García-Carrasco; J Yagüe; S Jiménez; G de la Red; R Cervera; J Font; M Ingelmo
Journal:  Medicine (Baltimore)       Date:  2001-07       Impact factor: 1.889

Review 2.  Hyperviscosity syndrome in cryoglobulinemia: clinical aspects and therapeutic considerations.

Authors:  Alessandra Della Rossa; Antonio Tavoni; Stefano Bombardieri
Journal:  Semin Thromb Hemost       Date:  2003-10       Impact factor: 4.180

3.  Rituximab inefficiency during type I cryoglobulinaemia.

Authors:  H Nehme-Schuster; A-S Korganow; J-L Pasquali; T Martin
Journal:  Rheumatology (Oxford)       Date:  2005-01-18       Impact factor: 7.580

4.  Studies of cryoglobulins; unusual purpura associated with the presence of a high concentration of cryoglobulin (cold precipitable serum globulin).

Authors:  A B LERNER; C J WATSON
Journal:  Am J Med Sci       Date:  1947-10       Impact factor: 2.378

5.  Cryoglobulinemia.

Authors:  Enrica Morra
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2005

6.  Increased risks of lymphoma and death among patients with non-hepatitis C virus-related mixed cryoglobulinemia.

Authors:  David Saadoun; Jérémie Sellam; Pascale Ghillani-Dalbin; Richard Crecel; Jean-Charles Piette; Patrice Cacoub
Journal:  Arch Intern Med       Date:  2006-10-23

7.  Biologic and clinical significance of cryoglobulins. A report of 86 cases.

Authors:  J C Brouet; J P Clauvel; F Danon; M Klein; M Seligmann
Journal:  Am J Med       Date:  1974-11       Impact factor: 4.965

8.  Hematologic malignancies in patients with cryoglobulinemia: association with autoimmune and chronic viral diseases.

Authors:  Olga Trejo; Manuel Ramos-Casals; Armando López-Guillermo; Mario García-Carrasco; Jordi Yagüe; Ricard Cervera; Josep Font; Miguel Ingelmo
Journal:  Semin Arthritis Rheum       Date:  2003-08       Impact factor: 5.532

9.  Prognostic factors of survival in patients with non-infectious mixed cryoglobulinaemia vasculitis: data from 242 cases included in the CryoVas survey.

Authors:  Benjamin Terrier; Fabrice Carrat; Evguenia Krastinova; Isabelle Marie; David Launay; Adeline Lacraz; Pauline Belenotti; Luc de Saint Martin; Thomas Quemeneur; Antoine Huart; Fabrice Bonnet; Guillaume Le Guenno; Jean-Emmanuel Kahn; Olivier Hinschberger; Patricia Rullier; Aurelie Hummel; Elisabeth Diot; Christian Pagnoux; Estibaliz Lzaro; Frank Bridoux; Thierry Zenone; Olivier Hermine; Jean-Marc Leger; Xavier Mariette; Patricia Senet; Emmanuelle Plaisier; Patrice Cacoub
Journal:  Ann Rheum Dis       Date:  2012-05-14       Impact factor: 19.103

Review 10.  Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients.

Authors:  P D Gorevic; H J Kassab; Y Levo; R Kohn; M Meltzer; P Prose; E C Franklin
Journal:  Am J Med       Date:  1980-08       Impact factor: 4.965

View more
  4 in total

Review 1.  The complexity of an overlap type resistant cryoglobulinemia: a case report and review of the literature.

Authors:  Milena Tocut; Ziv Rozman; Alexander Biro; Asher Winder; Amir Tanay; Gisele Zandman-Goddard
Journal:  Clin Rheumatol       Date:  2019-01-10       Impact factor: 2.980

Review 2.  Management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian Study Group of Cryoglobulinemia (GISC).

Authors:  Luca Quartuccio; Alessandra Bortoluzzi; Carlo Alberto Scirè; Antonio Marangoni; Giulia Del Frate; Elena Treppo; Laura Castelnovo; Francesco Saccardo; Roberta Zani; Marco Candela; Paolo Fraticelli; Cesare Mazzaro; Piero Renoldi; Patrizia Scaini; Davide Antonio Filippini; Marcella Visentini; Salvatore Scarpato; Dilia Giuggioli; Maria Teresa Mascia; Marco Sebastiani; Anna Linda Zignego; Gianfranco Lauletta; Massimo Fiorilli; Milvia Casato; Clodoveo Ferri; Maurizio Pietrogrande; Pietro Enrico Pioltelli; Salvatore De Vita; Giuseppe Monti; Massimo Galli
Journal:  Clin Rheumatol       Date:  2022-09-28       Impact factor: 3.650

Review 3.  Pigmented purpura and cutaneous vascular occlusion syndromes.

Authors:  Ana Cecilia Lamadrid-Zertuche; Verónica Garza-Rodríguez; Jorge de Jesús Ocampo-Candiani
Journal:  An Bras Dermatol       Date:  2018-06       Impact factor: 1.896

4.  Non HCV-Related Mixed Cryoglobulinemic Vasculitis With Biopsy-Proven Renal Involvement: The Effects of Rituximab.

Authors:  Roberta Fenoglio; Savino Sciascia; Daniela Rossi; Carla Naretto; Mirella Alpa; Dario Roccatello
Journal:  Front Med (Lausanne)       Date:  2022-03-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.